Celesio AG
http://www.celesio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celesio AG
European Notebook: EMA Meetings Go (Somewhat) Public; Walgreens’ Global Reach; Scottish Independence?
The European Medicines Agency moves closer to U.S.-style advisory committee meetings in public; two national referendums next month could hit Scotland’s biotech industry and Switzerland’s health insurance sector.
Actavis’ Big Bet On A Diversified Hybrid Model
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
European Notebook: Price Freezes, European Elections To Feature In 2014
This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.
Deals Of The Week: Eisai Shares Full Compound Library In Screening Partnership With JHU
Academic drug-discovery collaborations with industry usually are limited by restraints companies place on how much of their compound libraries they’ll share in a collaboration. Plus the week’s top deals, including M&A transactions between Teva and NuPathe, and Par Pharmaceuticals and JHP.
Company Information
- Industry
- Distributors
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice